Study Tracks Early Adoption of Liver Histotripsy Treatment
A retrospective cohort of 972 U.S. adults undergoing liver histotripsy revealed low short‑term toxicity but an 11.1% 30‑day mortality, highlighting concerns about its use near end‑of‑life and the need for comparative studies to guide patient selection.
This retrospective cohort study evaluated short‑term outcomes of liver histotripsy in 972 U.S. adults, finding low toxicity but a 30‑day mortality of 11.1%, underscoring concerns about use near end‑of‑life and the need for comparative studies to guide patient selection.
The adoption of liver histotripsy for metastatic and primary liver tumors raises questions about appropriate patient selection, especially given the high early mortality and lack of comparative data, warranting further investigation to establish its role in multidisciplinary cancer care.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics